reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. This evidence concerns the gene MAOB and Alzheimer disease.